Why MannKind Corporation Stock Briefly Soared

MannKind stock is birefly a big gainer after announcing a long-awaited licensing deal for its lead drug, Afrezza. Find out what this means for shareholders.

Aug 11, 2014 at 1:58PM

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of MannKind (NASDAQ:MNKD), a biopharmaceutical company focused on developing inhalable therapies to treat diabetes, surged by as much as 32% after announcing a global licensing agreement with Sanofi (NYSE:SNY) for its newly approved inhalable diabetes drug, Afrezza. Shares have since cooled dramatically and are now up a little over 6%.


Source: MannKind.

So what: According to the company's early morning press release, Sanofi will be responsible for all commercial, regulatory and development activities, while MannKind will handle the manufacturing of the drug, under a separate agreement. In the interim, both companies will collaborate on how to best expand manufacturing capacity beyond just MannKind's Danbury, Conn., facility. The two plan to launch Afrezza in the first quarter of 2015.

Under the financial terms of the deal MannKind will receive $150 million upfront, which will help stem cash burn concerns by investors, and is eligible to receive another $775 million in milestone payments. Perhaps more importantly for the long term, Sanofi will retain 65% of all profits and losses with MannKind receiving the remaining 35%. Sanofi is also advancing MannKind $175 million in collaboration expenses.

Now what: I believe the phrase that was collectively uttered when MannKind shareholders read this news was "About time!" MannKind had been getting dangerously low on cash, but everyone sort of knew that a deal was around the corner with Afrezza now approved.

The real test now comes with the launch and the price of the inhalable insulin product compared to existing type 1 and type 2 diabetes therapies. From a factor of convenience there is no comparable product, therefore Afrezza has a step up on the competition in that respect. But, how quickly insurers and physicians jump on board remains to be seen. Having Sanofi in its corner is a definite step in the right direction, but I'd rather hold off and wait for concrete earnings growth and a discernable move toward profitability rather than risk being caught up in a drug that could just as easily stumble out of the gate.

Afrezza's opportunity is huge, but it may wind up eating the dust of this revolutionary new technology in terms of growth potential.
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers